The most useful preparation for a weight-management prescription is a clear picture of your health, goals and daily life. It is less useful to arrive with a drug selected from a ranking and no plan for follow-up. A good first conversation should establish what treatment is intended to achieve and how benefits, symptoms and practical barriers will be assessed.
There is no single checklist that determines whether a medicine is right for an individual. The questions below organize information for a clinician-led decision. They draw on agency guidance and current product labels checked on 3 October 2026, while leaving eligibility, testing and prescribing to your care team.
What problem are we trying to improve?
Begin with the reason for considering treatment. Weight reduction may be one goal alongside diabetes management, mobility, sleep symptoms or another health concern. Ask which goal the proposed medicine addresses, what evidence supports it and what outcome will be used to judge progress. A number on the scale should not silently stand in for every health outcome.
NIDDK describes prescription medicines as part of a broader weight-management plan that includes eating, activity and support. The appropriate approach depends on health history, other medicines and individual circumstances. The page is useful for that general role, but it is not a complete inventory of the newest approvals. For a particular medicine, current regulatory labeling takes priority.
A meaningful goal can be described without imposing a target borrowed from someone else’s before-and-after story. Ask what a reasonable review point would be, which health measures are relevant and what counts as a benefit worth continuing. The response may be different for a person treating diabetes than for someone pursuing an obesity-specific indication. Clarifying the goal early also makes later decisions about tolerability less arbitrary.
Which exact product and local indication are we discussing?
Write down the brand, active ingredient, route and country. These details prevent confusion when one molecule appears in several products. For example, the current US Wegovy label has different indication lists for injection and tablets. The US Zepbound label includes defined adult weight-management and sleep-apnea uses. Neither list should be expanded into approval for every health problem linked with weight.
Ask whether the proposed use is within the local approved indication and, if not, why the clinician considers an off-label approach. That question is about understanding the decision, not challenging every judgment outside a label. Off-label prescribing still involves an approved product; it should not be confused with an unapproved online product claiming to contain the same ingredient.
The consultation should also identify the supplied presentation. A device demonstration or tablet-timing discussion may be needed before the first use. An unexpected dispensing substitution is a reason to contact the pharmacist. Do not infer equivalence from a similar name, a shared ingredient or a smaller package.
Which health history could change the decision?
Bring a list of diagnoses, prior operations and significant symptoms, including previous reactions to medicines. Relevant concerns can include digestive problems, gallbladder or pancreatic history, kidney disease, diabetes and diabetic eye disease. The exact relevance varies by medicine. A checklist can prompt disclosure but cannot classify a person as safe or unsafe without clinical assessment.
For GLP-1-related products carrying the US thyroid warning, discuss personal or family history of medullary thyroid carcinoma and MEN 2. A vague family history of ‘thyroid trouble’ may need clarification. It should not be assumed to mean the same diagnosis, and it should not be dismissed without checking. Our thyroid-warning article explains why specificity matters.
Tell the team about pregnancy plans, possible pregnancy, breastfeeding and contraception. These may alter treatment timing and the broader care plan. Do not postpone the discussion until an appointment devoted only to weight loss. A person using a medicine for diabetes may need coordinated ongoing glucose treatment when pregnancy plans change. Pregnancy planning covers the product-specific questions.
Can we review all medicines together?
Include insulin, other diabetes treatments, pain medicines, psychiatric medicines, oral contraceptives, nonprescription products and supplements. ‘Natural’ products belong on the list too. The interaction review is not limited to whether two medicines share a mechanism; it can involve absorption, low blood glucose, blood pressure or other product-specific concerns.
Tirzepatide labels, for example, include a particular precaution for oral hormonal contraception after starting and after dose increases. Other products have different instructions. Ask the prescriber or pharmacist to identify the rules that apply to your actual medicines. Do not stop an established medicine independently because an article mentions a possible interaction.
A useful list includes how each product is actually taken, rather than just its name in an old medical record. If different specialists prescribe different medicines, ask who will coordinate changes. The purpose is to make the treatment plan coherent before a new prescription adds complexity.
What should happen during escalation and symptoms?
Ask for the prescribed schedule in writing, the reason for gradual increases and the contact route if symptoms make the next step difficult. Current GLP-1 product labels use escalation partly to reduce gastrointestinal adverse reactions. The appropriate plan is not a race to the largest labeled dose. The escalation guide explains that distinction.
Clarify what to do if a dose is missed, treatment is interrupted or access changes. Instructions differ by product and duration of the interruption. A generic internet answer can be wrong for the presentation supplied. Ask which symptoms warrant prompt contact and which require urgent evaluation. Severe or persistent abdominal pain, repeated vomiting or inability to keep fluids down should not simply be accepted as routine weight-loss treatment.
Also ask how nutrition and hydration will be reviewed. A lower appetite should not make adequate intake, strength and normal activities disappear from follow-up. Support can be individualized when symptoms or a restricted routine make eating difficult. This is an opportunity to plan assistance before a problem becomes urgent.
What does the full treatment year require?
Ask about appointments, monitoring, costs, refill logistics and likely duration. Coverage for an initial prescription is not proof of coverage for ongoing treatment. A pharmacy’s current stock is not a guarantee of uninterrupted supply. These practical issues matter because starting without a continuation plan can create avoidable uncertainty.
Discuss maintenance and possible discontinuation at the start. Withdrawal trials show that stopping some effective therapies can lead to substantial regain, but that does not mean every person must continue every medicine indefinitely. Decisions may change because of pregnancy, adverse effects, benefits or access. The point is to have a review process and support plan rather than discover those questions only when treatment stops.
Before leaving, summarize the intended outcome, exact product, follow-up date and symptom-contact plan in your own words. Ask the team to correct any misunderstanding. A successful starting conversation produces a shared plan, not simply a prescription. That plan makes it easier to evaluate progress fairly and respond to problems early.
